Factor XI Deficiency

Hematol Oncol Clin North Am. 2021 Dec;35(6):1157-1169. doi: 10.1016/j.hoc.2021.07.012. Epub 2021 Sep 15.

Abstract

Factor XI (FXI) deficiency (hemophilia C or Rosenthal disease) was first described in the 1950s in a multigenerational family experiencing bleeding related to surgery and dental procedures. Managing patients with FXI deficiency presents several challenges, including a lack of correlation of bleeding symptoms with FXI activity levels, the large volume of fresh frozen plasma required to achieve hemostatic FXI levels, lack of availability of FXI concentrate in certain regions of the world, and the inherent thrombotic risk associated with replacement therapy. This article summarizes presentation, diagnosis, and management of patients with FXI deficiency in a variety of clinical settings.

Keywords: Factor XI deficiency; Hemophilia C; Plasma thromboplastin antecedent deficiency; Rosenthal syndrome.

Publication types

  • Review

MeSH terms

  • Factor XI
  • Factor XI Deficiency* / diagnosis
  • Factor XI Deficiency* / therapy
  • Hemorrhage / etiology
  • Hemostasis
  • Humans
  • Thrombosis

Substances

  • Factor XI